


GALEN GROWTH

Digital Health 2025 Funding and Key Trends

Clearing the Bottleneck: How Digital Innovation is Driving Clinical Trials

Investment Trends • Pipeline Maturity

Category Focus • Proof Points

Therapeutic Focus • Noteworthy Deals

Partnerships • Alpha Forecaster

The Bottleneck and the Path Forward

The Bottleneck

Clinical trials are a critical constraint in global drug development, consuming over half of total R&D costs and stretching timelines by years.

Despite significant advances in TechBio and AI-driven discovery, progress stalls once trials begin. Recruitment delays, data fragmentation, and regulatory complexity now define the most expensive and time-consuming stage of innovation.

The Turning Point

The tools to change this already exist.

AI-powered design, digital recruitment, and decentralised trial platforms have proven they can shorten timelines, expand inclusion, and improve success rates.


Health systems and regulators — from the NHS's open trial databases to the FDA's digital evidence frameworks — are building the infrastructure for scale.

The Path Forward

Yet capital remains misaligned: funding for clinical trial ventures has fallen 46% in five years, slowing adoption precisely when demand is highest.

Unlocking faster, smarter, and more inclusive trials will require targeted investment, regulatory alignment, and bold collaboration between pharma, investors, and digital innovators.

The future of drug development depends on fixing the trial bottleneck — and Digital Health holds the key.



HEALTHTECH ALPHA

© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Key Insights

3%

Venture Share

Clinical Trials remains one of the smallest Digital Health clusters, capturing only **3% of global Digital Health ventures**. The growth of ventures offering solutions for clinical trials in Digital Health outpaces the global Digital Health 5-year CAGR by two percentage points, indicating a vigorously growing ecosystem with highly relevant solutions.

-46%

Funding Decline

Clinical trials are growing more complex, and the need for smarter, safer technology has never been greater. **Global funding for the cluster has declined by 46% over the past 5 years,** leaving ventures without the means to scale. Compared to the overall global Digital Health ecosystem, the share of funding deployed to clinical trial ventures has decreased 30% from 6.9% in 2020 to only 4.8% in 2024.

17%

Exits

Investment in digital technology for clinical trials is a compelling opportunity. While the number of trials remains largely constant, the time and cost required to run them continue to rise, creating pressure on R&D organizations to do more with less. Startups focused on clinical trials already account for the **highest share of exits (17%) across all Digital Health clusters**, demonstrating strong demand and a highly active market for innovative solutions.

10%

Series A

Many ventures with digital solutions for clinical trials must survive with limited resources while demonstrating that their solutions can bring efficiency increases to the industry, particularly with limited. Only **10% of the ventures incorporated over the past 5 years have been successful in raising a Series A** funding round. Once established, however, growth and late-stage funding is more common, and 25% of ventures founded before 2017 have exited.

99%

AI

As of 2025 YTD, **99% of funding for clinical trial ventures** has gone to companies developing **AI-powered solutions**. Reflecting this clear market opportunity, **89% of ventures founded between 2023 and 2025 YTD** have incorporated AI into their offerings — a significant increase from **69% of ventures founded before 2023** — underscoring the accelerating adoption of AI as a **key differentiator** in the clinical trials space.

© 2025 by Galen Growth - All rights reserved.

Digital Health - Innovating Across the Entire Healthcare Value Chain



Digital Health is not just about patient-facing solutions, such as mobile apps or telemedicine platforms. **It's a revolutionary ecosystem of digital and technological innovations permeating every link of the healthcare value chain**. Digital Health is redefining how healthcare operates at every level, from drug discovery and development to clinical trials, supply chain optimisation, diagnostics, hospital management systems, insurance, and regulatory compliance.

By embracing this expansive view, we recognise that digital transformation impacts all facets of healthcare. Cutting-edge technologies like artificial intelligence, machine learning, IoT, and blockchain optimise operational efficiencies, enable personalised medicine, and foster collaboration among stakeholders — not just improve patient outcomes.

Galen Growth's industry-standard taxonomy captures this comprehensive perspective, highlighting that every touchpoint along the healthcare continuum is a critical part of the Digital Health landscape. This holistic approach allows stakeholders to uncover innovation opportunities beyond patient interfaces and appreciate the profound potential of Digital Health in data analytics, medical devices, pharmaceutical processes, and healthcare delivery infrastructure.

Digital Health, as defined by Galen Growth, is a **dynamic, all-encompassing ecosystem** where innovation seamlessly integrates across the entire healthcare value chain, far exceeding the confines of patient solutions alone.

Refer to slides 72 and 73 for additional details on our taxonomy.

© 2025 by Galen Growth - All rights reserved.

Data & Methodology

Source of Data

Unless otherwise stated, all data are exclusively sourced from Galen Growth's proprietary database **HealthTech Alpha™** – the global leading Digital Healthcare Technology Innovation data, intelligence and insights platform. Currently, HealthTech Alpha tracks over 1 billion data points and has coverage exceeding 16,000 Digital Health ventures worldwide. For more information, visit https://www.healthtechalpha.com/

Data Scope

The 2025 Digital Innovation in Clinical Trials report examines Digital Health ventures worldwide. Ventures that have solutions in the Digital Health cluster of Clinical Trials, according to Galen Growth's Taxonomy, are selected for the analysis.

The following scope of analysis criteria must be met to be included in this report:

- The venture was incorporated after 2002
- The venture has been classified as Digital Health, i.e., Galen Growth's rigorous taxonomy - see slide 72
- The venture's geographic location is determined by its initial country of incorporation.
- Venture funding includes all stages up to but excluding the exit event
- Subsidiaries of large corporations (e.g. Microsoft) are excluded



Explore 16,000+ Ventures
In HealthTech Alpha

Methodology

Analytics presented in this report are Galen Growth's proprietary algorithms and are explained on slide 73.

© 2025 by Galen Growth - All rights reserved.



GALEN GROWTH

Contents

8 Clinical Trials: The Bottleneck

22 Ecosystem Insights

30 Investment Insights

40 Category Focus

46 Therapeutic Focus

51 Snapshots

- 52 United States
- 59 Europe
- 64 Asia Pacific

69 Key Information

Trusted Industry Insights – Galen Growth Research



Unmatched Expertise & Data-Driven Insights

High-quality, actionable research and insights for investors, corporates, and startups.

Powered by HealthTech Alpha

The leading intelligence platform for Digital Healthcare Technology

No Hype. No Bias. No Anecdotes

Purely data-driven insights, ensuring objective, evidence-backed analyses.

Digital Health Experts, Not Generalists

Led by industry veterans, not generalist analysts with little sector expertise.

Over a Decade of Digital Health

A proven track record of unmatched industry data and thought leadership.

Independent & Agenda-Free

Our insights are driven by data and expertise, not sponsorships.

Make Informed Decisions

Gain the competitive edge with **Galen Growth's trusted, unparalleled research.**

Clinical Trials

The Next Frontier in Efficient Drug Development:

Clinical Trials

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Clinical Trials: The Persistent Bottleneck

Clinical trials remain the most expensive and time-consuming stage of drug development, often accounting for more than half of total R&D spend. A single trial can cost anywhere from $1 million to over $100 million, with an average cost of $15,000 – 50,000 per patient[1]. Delays in patient recruitment are among the biggest drivers of overruns. Other cost pressures stem from regulatory compliance, site management across multiple geographies, and the complexity of novel therapies, such as cell and gene treatments. The result is rising R&D costs, slower innovation, and longer waits for patients to access potentially life-saving drugs.

At the same time, the pharmaceutical industry faces mounting pricing pressure — from UK rebate schemes exceeding 30% to US drug price negotiations — making it harder to recoup the soaring development costs.

Key drivers of rising costs and delays:

- Patient recruitment and retention challenges
- Complex regulatory and compliance requirements
- Expensive data management and monitoring
- Multicenter/global trial logistics
- Advanced therapy complexity (e.g., precision medicine, biologics)

The outcome? **Innovation stalls, R&D costs keep climbing, and patients face longer waits for access to potentially life-saving treatments.**

R&D cost per pipeline asset, 2013 - 2024



Source: Measuring the return from pharmaceutical innovation | Deloitte UK

1) The Ultimate Guide to Clinical Trial Costs in 2025, Sofpromed


© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Post-TechBio Boom: Time to Introduce AI to Clinical Trials


Over the past four years, significant venture capital investment in TechBio has fueled breakthroughs, including advanced predictive models in structural biology — most notably, AI systems such as AlphaFold — that have dramatically improved efficiency in target identification and molecule design. These gains demonstrate how capital can accelerate discovery; however, the bottleneck now lies in clinical trials. To truly shorten timelines and reduce costs, investment must shift toward modernising trials and integrating AI tools into this critical stage of the development process.

Global venture capital investment in Digital Health and share of investment deployed to ventures with solutions for TechBio and Clinical Trials



Source: HealthTech Alpha

TechBio: +75%



Share of Digital Health Funding



Clinical Trials: -30%


© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Clear Investment Signals for AI-based Tools

Surging investment in AI-driven clinical trial technologies is transforming how studies are designed, conducted, and analyzed — enabling faster recruitment, smarter protocol optimization, and real-time insights that boost efficiency and accuracy. This momentum is fueled by unprecedented investor confidence: **in 2025 year-to-date, 99% of all Clinical Trials venture funding has gone to companies leveraging AI**, including leaders like Pathos and Lindus Health, signaling a decisive shift toward intelligent, data-powered research.


Share of Clinical Trial Funding Deployed to Ventures using AI Technology, by Year




Source: HealthTech Alpha

Recognizing a clear market opportunity, **89% of Clinical Trials ventures founded between 2023 and YTD 2025** have embedded AI into their solutions — **a sharp rise from 69%** among ventures established before 2023 — highlighting the accelerating adoption of AI as a core differentiator in this space.

Share of Ventures Using AI Technology





Source: HealthTech Alpha

© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Business Case for Innovation

Clinical trials are becoming increasingly complex, with more endpoints, stricter eligibility criteria, and added procedures slowing recruitment and extending timelines. At the same time, the pandemic accelerated the adoption of digital and remote methods, sparking an innovation cycle that continues to mature. Today, digital platforms and decentralised trial models present a significant opportunity to counter complexity, streamlining recruitment, enhancing patient engagement, and improving transparency. With regulators now issuing clear guidance and health systems, such as the NHS, building public trial databases, digital innovation is poised to transform trials into faster, more inclusive, and more efficient engines of medical progress.

Key enablers of this shift include:


Decentralised trial infrastructure, including home monitoring, wearables, and telehealth, reduces patient burden and expands access across geographies.

Smarter recruitment and retention tools, including AI-driven patient matching, EHR integration, and digital outreach, speed up enrollment while improving diversity.

Data transparency and trust: Public trial registries and interoperable platforms enable patients, clinicians, and regulators to track progress in real-time.

Enrollment remains the most important addressable opportunity to accelerate trials, having increased by nearly three months since 2021

Exhibit 58: Median duration benchmarks by study interval (months), Phase I to III combined, 2015 to 2024




Source: Citeline Trialtrove, Jan 2025; IQVIA Institute, Jan 2025; Getz et al, Therapeutic Innovation & Regulatory Science 57 (2023) 49–56.

© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Investment into Clinical Trials Technology Is A Good Bet

Share of Ventures with M&A, IPO or SPAC, by Digital Health Cluster




Source: HealthTech Alpha

Investment in digital technology for clinical trials is a compelling opportunity. While the number of trials remains largely constant, the time and cost required to run them continue to rise, creating pressure on R&D organizations to do more with less. Startups focused on clinical trials already account for the **highest share of Exits across all Digital Health clusters**, demonstrating strong demand and a highly active market for innovative solutions.

Yet, despite this traction, funding and partnerships for clinical trial technologies remain subscale. This gap means that many promising solutions are not reaching the scale or adoption needed to transform the process truly. For investors seeking exits and for R&D teams leveraging GenAI to boost efficiency, this represents a clear—and currently underexploited—opportunity, with the potential to both accelerate drug development and generate significant returns.

Number of commercial Clinical Trials, by start year



Source: Evaluate Pharma

© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Digital Innovation in Clinical Trials

During the pandemic, researchers were forced to rapidly adopt **remote and digital methods** to keep studies running. What began as a crisis-driven necessity has since evolved into a durable innovation cycle, with solutions that reach across the clinical trial process.

Galen Growth's Taxonomy of Digital Health Solutions for Clinical Trials

	Digital Health Category	Definition	Share of Clinical Trial Ventures with Solutions in this Category*
 **Clinical Trials**	**Clinical Trial Design**	Digital solutions that assist in the design of Clinical Trials, including protocol development, protocol writing, sample selection, and more	14%
	Clinical Trial Matching	Technologies that use collections of patient data or networking technology to facilitate patient enrolment in clinical trials	41%
	Decentralised Clinical Trials	Digital solutions that support the delivery, risk management, and/or administration of a clinical trial where portions of the trial may occur without any face-to-face interaction between the trial participant and the study investigator.	40%
	Data Collection Tools	Technologies that support the collection of data such as biomarkers, patient behaviour or patient reported outcomes during a clinical trial	31%

Source: HealthTech Alpha

* Ventures can have solutions in multiple categories

© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Clinical Trial Design

More than half of the costs associated with developing a new drug are incurred during the clinical trial phase, the most time- and resource-intensive stage of the development process. Deploying **AI to design clinical trials** is transforming this process by analyzing large datasets from previous studies, bioinformatics resources, and regulatory filings to identify optimal trial parameters. By leveraging **digital tools for clinical trial design**, researchers can select the most appropriate patient populations, optimize study protocols, set effective compliance measures, and implement robust risk-monitoring strategies.



Clinical Trial Design innovation not only **reduces drug development costs** by minimizing trial failures but also improves outcomes by enhancing statistical power, reducing variability, and accelerating recruitment. Ultimately, AI-driven clinical trial design enables smarter, data-driven decisions, making trials faster, more reliable, and cost-efficient, while **maximizing the likelihood of regulatory success**. Recent statistics, as shown in the chart, indicate that more clinical risk is being successfully shifted to Phase I and Phase II testing, thereby increasing the success rate of Phase III trials and regulatory submissions.


Share of Clinical Trial Design Ventures using AI Tools



86% of Ventures in Clinical Trial Design use AI tools

Source: HealthTech Alpha

Phase Success rates, Phase I to approval, 2015 - 2024



Sources: Citeline Pharmapremia, Jan 2025; IQVIA Institute, Jan 2025.

© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Clinical Trial Matching

One of the most significant barriers in clinical trials remains **patient recruitment**—finding and enrolling participants who meet strict eligibility criteria. Traditionally, this process has been slow, labour-intensive, and dependent on manual review of medical records. Artificial intelligence is rapidly changing this landscape. A recent study, highlighted by *Fierce Biotech*, showed that an AI model could **match patients to clinical trials as quickly as a human recruiter, with only a slight dip in accuracy**, but with the potential to operate at far greater scale and speed (Fierce Biotech).


Meanwhile, researchers at the **National Institutes of Health (NIH)** have developed a large language model called **TrialGPT**, which is capable of scanning patient medical summaries and automatically identifying trials for which patients are eligible. Published in *Nature Communications*, this breakthrough demonstrates how LLMs can not only accelerate trial matching but also enhance inclusivity by identifying opportunities that may otherwise be overlooked in manual reviews—allowing clinicians to focus on patient engagement while AI handles the initial, time-consuming task of eligibility screening.

As digital trials become more sophisticated, the **number and complexity of eligibility criteria**—particularly in Phase I trials—**are rapidly increasing** *(see slide 17)*. These early-stage studies often require highly specific patient profiles, including genetic markers, comorbidities, and prior treatment histories, making manual screening even more impractical. This **growing complexity underscores the urgent need for innovation.**

Digital health ventures are turning AI- and LLM-driven innovations from experimental concepts into practical, real-world solutions for clinical trial recruitment. By accelerating the identification of eligible participants, these tools enable trials to launch more quickly, achieve enrollment targets more consistently, and bring therapies to patients sooner. This shift is being **driven by robust investment**: in the 2025 year-to-date period, 99% of funding in clinical trials ventures has gone to companies leveraging AI technology.



Share of Clinical Trial Matching Ventures using AI Tools



71% of Ventures in Clinical Trial Matching use AI tools

Source: HealthTech Alpha

© 2025 by Galen Growth - All rights reserved.


FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Decentralised Clinical Trial Platforms

The increasing number of eligibility criteria and endpoints is driving up the complexity of clinical trials, creating pressure for more sophisticated digital tools. **Decentralised and digital-first trial platforms**—including remote monitoring, telemedicine, eConsent, and wearable devices—enable participants from rural and underserved areas to participate without frequent travel, thereby improving inclusion, retention, and trial timelines. At the same time, **AI-driven monitoring and risk management** can predict adverse events, recommend early adjustments, or flag failing trials, ensuring patient safety and maximizing the likelihood of success. Real-time supervision enables immediate corrective action, rather than waiting until a trial concludes, thereby reducing costs and making complex trials more manageable and efficient. Ventures in Decentralised Clinical Trials have been the most frequent exits targets over the past 5 years.




Distribution of categories for ventures within the Clinical Trials Cluster that have been acquired from 2021 – YTD 2025



Source: HealthTech Alpha

Average eligibility criteria, endpoints per trial, 2015 - 2024



Source: Citeline Trialtrove, Jan 2025; IQVIA Institute, Jan 2025.

© 2025 by Galen Growth - All rights reserved.


FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Data Collection Tools

Digital Data Collection Tools and wearable devices are enabling **digital-first clinical trials**, allowing participants from rural and underserved areas to join without frequent travel, which boosts inclusion, retention, and speeds up completion while optimising clinical resources. **Cloud platforms, blockchain-secured consent, and ePRO systems** streamline data flows for integrating remote devices and maintain the regulatory-grade integrity required. **AI-powered anomaly detection and data cleaning make datasets compile faster and more reliably, while real-time data collection enables continuous risk monitoring and immediate corrective action, preventing trial outcomes from being** compromised. A survey of 8 biopharma companies[2] concluded that data collection tools are currently being used in clinical trials, and respondents anticipate a significant increase in their use, expecting adoption rates to rise by over 40% within five years to enhance patient-centricity and trial accessibility.



Current Adoption Rate of Remote Monitoring and Data Collection Technologies in Oncology Trials Compared With Average Aspired Adoption Rate in 5 Years *(survey of 8 biopharma companies)*[2]



2) Remote Monitoring and Data Collection for Decentralized Clinical Trials, JAMA Netw Open. 2024;7(4):e246228. doi:10.1001/jamanetworkopen.2024.6228

© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


More Investment Is Needed

Clinical trials are growing more complex, and the need for smarter, safer technology has never been greater. Global funding for the cluster has declined by 46% over the past five years, leaving ventures without the means to scale and mature, which has led to early M&A activity for high-potential solutions.

Challenges in this space include:

- **Procurement risk > novelty:** Sponsors favor GxP-validated suites or CRO bundles, making enterprise deals difficult for start-ups.
- **ROI is dispersed:** Benefits such as faster site start-up and fewer protocol amendments accrue across functions, slowing adoption in cautious capital expenditure environments.
- **Regulatory and operational hurdles:** Inconsistent regulatory acceptance, rising endpoints and eligibility criteria, and EHR integration challenges increase execution risk.
- **Strategic focus:** Many R&D organizations have prioritized GenAI for low-risk areas before extending into regulated trial operations.

Digital and AI-enabled tools offer the opportunity to de-risk trials, streamline complex operations, deliver measurable impact across phases, and accelerate both adoption and patient access to new therapies.




Source: HealthTech Alpha

© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Working Together Toward the Same Goal



© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

The Time for Investment and Partnerships Is Now

We are at a pivotal moment. The technologies to make trials faster, cheaper, more inclusive, and more reliable already exist. What's needed is strategic funding, regulatory alignment, and bold partnerships to scale these innovations across the industry. Ventures within this cluster have already led the way in successful exits, and emerging shifts promise to drive even greater innovation:




Trial model: Hybrid/decentralised becomes standard, bringing studies to patients via telehealth, home nursing, community sites, and direct-to-patient logistics.



Data fabric: Continuous streams from wearables/ePROs and tighter EHR/RWD integration unlock patient-centric, objective endpoints.



AI in operations: Targeted use cases (feasibility, site/patient selection, risk-based monitoring, coding, data QA) drive practical productivity, not "automate-everything" moonshots.



Platforms & interoperability: Cloud eClinical stacks (EDC/eConsent/ ePRO/CTMS) integrate with sponsor data lakes and CRO tooling; APIs and standards become table stakes.



Regulatory posture: Growing comfort with digital measures and remote procedures—raising the bar on validation, auditability, privacy, and GCP compliance.

Over the past two years, the focus has been on TechBio's potential to accelerate drug discovery. Now, the next two years must center on implementation—turning clinical trials **from bottlenecks into catalysts for drug development efficiency**. Because at the end of the day, efficient clinical trials don't just accelerate R&D pipelines—they deliver **life-saving treatments** to patients who need them, faster than ever before.

© 2025 by Galen Growth - All rights reserved.

Clinical Trials


Ecosystem Insights

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Clinical Trial Ventures Outpace Global Ecosystem Growth

The growth of ventures offering solutions for clinical trials in Digital Health outpaces the global Digital Health 5-year CAGR by two percentage points, indicating a vigorously growing ecosystem with highly relevant solutions.

Global Share of Ventures with Solutions for Clinical Trials



Cumulative Volume of Private & Active Ventures, 2020 – 2024



Note: venture volume for recent years is expected to increase as ventures emerge from stealth


© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Largest Ecosystems Focus on Critical Pain Points

Data from Citeline (slide 12) show that **clinical trial matching remains the most time-consuming stage** of the trial process, with its duration increasing by **21% since 2021**. In the two largest regions—**North America and Europe**—over **30% of ventures** are focused on addressing this critical bottleneck. In contrast, ventures founded in **APAC and the Middle East** are prioritizing **decentralised clinical trial management tools (or Decentralised Clinical Trials)**, with nearly **half of all ventures** in these regions targeting this area. This focus reflects a fundamental regional challenge: the **lack of underlying infrastructure** for trial administration, which has historically limited the ability to conduct trials efficiently.

Global Proportion of Ventures



Share of Clinical Trials Ventures with Solutions in each Category*, by Region



*Note: Ventures can have solutions in multiple categories


© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Ventures Can Expect a Slow Start

Ventures with digital solutions for clinical trials must demonstrate that their solutions can bring efficiency increases to the industry, particularly with limited resources, as many ventures struggle to survive during this challenging time. Only 10% of the ventures incorporated over the past 5 years have been successful in raising a Series A funding round, while seven ventures have become inactive, and 1 has been acquired. Once established, however, growth and late-stage funding is more common, and 25% of ventures founded before 2017 have exited.

Global Distribution of Clinical Trials Ventures by Current Funding Stage and Venture Incorporation Year



© 2025 by Galen Growth - All rights reserved.


FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Venture-to-Venture Collaboration is Integrating the Clinical Trial Ecosystem


The widespread adoption and impact of digital solutions for clinical trials rely on the collaboration of key healthcare stakeholders.

Like other sectors within Digital Health, venture-to-venture partnerships help eliminate fragmented point solutions, enhancing convenience for consumers. By working closely with healthcare providers and pharmaceutical companies, ventures in this sector can develop solutions that are better integrated into their customers' workflows and facilitate a smoother transition from legacy systems.

Growth of Partnerships in Clinical Trials by Quarter and Region



2024 – YTD 2025 Venture Partnership Distribution by Digital Health Cluster




© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Health Systems Increasingly Relying on Digital Clinical Trials Tools

Over the past five years, partnerships between health systems and clinical trial ventures have grown steadily as both sectors recognize the need for decentralised clinical trials and the value of integrating real-world clinical data and patient access into research operations. Health systems provide a trusted infrastructure and diverse patient populations, while clinical trial ventures bring advanced digital tools that streamline study design and execution. Notably, more than half of these collaborations now center on solutions that enable and manage decentralised clinical trials, reflecting a shift toward more patient-centric, data-driven research models.

Growth of Partnerships between Health Systems and Clinical Trials Ventures by Year and Region



Health Systems Partnership Distribution by Digital Health Category (2021 – YTD 2025)




© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Biopharma Turns to Digital Tools for Clinical Trial Efficiency

Pharma companies are increasingly turning to digital solutions to manage the growing complexity of clinical trials, where stricter eligibility criteria and additional endpoints have made recruitment and execution more challenging. The rise of decentralised models—powered by telehealth, wearables, and remote monitoring—helps expand patient access, reduce burden, and improve engagement across diverse populations. At the same time, AI-driven matching tools, EHR integration, and interoperable data platforms are streamlining recruitment, enhancing transparency, and transforming clinical trials into faster, more efficient, and more inclusive engines of innovation.

Growth of Partnerships between Biopharma and Clinical Trials Ventures by Year and Region



Biopharma Partnership Distribution by Digital Health Category (2021 – YTD 2025)




© 2025 by Galen Growth - All rights reserved.

HEALTHTECH ALPHA

Access all the data behind this report and conduct your own analysis with *Alpha Edge*

Get started



Clinical Trials


Investment Insights

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Low Investment in Clinical Trials Weakens the Ecosystem

Clinical trials are growing more complex, and the need for smarter, safer technology has never been greater. Global funding for the cluster has declined by 46% over the past 5 years, leaving ventures without the means to mature. Compared to the overall global Digital Health ecosystem, the share of funding deployed to clinical trial ventures has decreased from 6.9% in 2020 to only 4.8% in 2024.

Funding for Clinical Trials Ventures and Share of Total Global Funding Value Captured by Clinical Trial Ventures, 2020-2024




© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Quarterly Analysis Shows Funding Fluctuation

Global funding for the Clinical Trials cluster declined over 2025 and hit a five-year low in Q1 2025, while quarterly deal activity has been consistently inconsistent, with peaks and valleys since 2022. The average deal size has been steadily increasing since early 2023, reaching $49.1 million at the end of the first half of 2025.




© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

2024 – YTD 2025 Regional Funding Distribution

Region	Total Funding (% change from 2023 to 2024)
North America	$1.7B ▲ (62%)
Europe	$390B ▲ (58%)
Asia Pacific	$11M ▼(-93%)
Middle East	$78M ▼(-95%)
South America	$0M —
Africa	$0M —


Total Funding (2024 – YTD 2025), by Region and % change from 2023 to 2024



FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

QoQ Digital Health Regional Funding History

The funding uptick for Clinical Trials in Q2 2025 was primarily attributed to the surge in funding in Q2 for North America, led by the $365 million Series D mega deal for Pathos, a Bioinformatics and Clinical Trial Design venture. Clinical Trial funding was absent from APAC in Q4 2024 and in 2025 YTD.



© 2025 by Galen Growth - All rights reserved.


FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Late-Stage Funding Boosts Clinical Trial Ventures


There was a noticeable shift in global funding distribution in 2023, with Europe increasing its share from a quarter of the worldwide funding volume to nearly 40%, while APAC and North America both lost a significant share. Europe has maintained a substantial share in the global investment volume, while North America continues to lose share.

Over the past two years, investors have allocated the largest share of funding value to late-stage (Series D & beyond) funding rounds.

Venture Funding Value by Funding Stage



Share of Investment Volume (2020 – YTD 2025)




© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Mega Deals (≥$100M) Tracker

The number of mega deals for ventures in clinical trials has remained low since 2022, with all but one deal being deployed to ventures in North America. The high M&A count for this cluster suggests that a large share of high-potential ventures are acquired before reaching late-stage growth.

Historical Volume of Mega Deals



Regional Distribution of Mega Deals




© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


M&A Is Dominated By Venture-to-Venture Acquisition

M&A activity in the Clinical Trials cluster is dominated by venture-to-venture acquisitions, accounting for 75% of deals year-to-date in 2025. Ventures are leveraging acquisitions to expand their technology capability and market presence, a trend further fuelled by sluggish funding, which has made acquisition targets more affordable.

Volume of Investor Exits (IPO, M&A, SPAC)



Acquisition Share of Digital Health Ventures, by Industry Vertical and Year



© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Global Digital Health Investor Participation

The average ticket size increased to $49 million in Q2 2025 for ventures in the Clinical Trials cluster, indicating increased investor confidence in the sector's growth. Merck Global Health Investment Fund (GHI), McKesson Ventures, and GV top the list as the most prolific investors in the sector (not including accelerators and government grant programs), participating in more than 42 Digital Health deals. See Galen Growth's HealthTech 50 Core Investors 2024 report for a deeper look at Digital Health investors in the overall Digital Health space.

Global Top 5 most active VC investors in Clinical Trials


Investor	Type	# of Digital Health Investments	# of Clinical Trials Investments	Recently Participated Investment	Date	Deal Value
Merck Global Health Investment Fund (GHI)	Corporate Venture Capital	96	17	N-Power Medicine	07 / 2024	undisclosed
McKesson Ventures	Venture Capital	66	13	Mural Health	08 / 2024	$13M
GV	Corporate Venture Capital	153	12	Paradigm	01 / 2023	$203M
Khosla Ventures	Venture Capital	198	11	Lightship	10 / 2021	$40M
Lux Capital	Venture Capital	103	11	Paradigm	01 / 2023	$203M

© 2025 by Galen Growth - All rights reserved.

HEALTHTECH ALPHA

Access all the data behind this report and conduct your own analysis with *Alpha Edge*

Get started



Clinical Trials

Category Focus

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Galen Growth's Digital Health Taxonomy™ – the industry standard

Health Management Solutions
- EHR / PHR
- Hospital
- Pharmacy
- Physician / Clinic
- Prescriptive Analytics

Health Services Search
- Healthcare Navigation
- Medical Concierge
- Medical Tourism
- Triage

Health InsurTech
- Health Claim Management
- Health Insurance
- Medical Payments

Medical Diagnostics
- Diagnosis Tools
- Medical Imaging
- Omics Related Diagnosis

Medical Education
- Consumer Education
- HCP Education
- Health Information Platform

Online Health Communities
- Other HCP Networks
- Patient Health Forums
- Physician Networks

Online Marketplace
- Consumer Marketplace
- On-demand Lab Tests
- Online Pharmacy
- Professional Marketplace

Patient Solutions
- Digital Therapeutics
- Disease Management
- Health / Symptom Checker
- Medication Management

Population Health Management
- Care Coordination
- Corporate Health
- Home Healthcare
- Integrated Solutions

Remote Devices
- Assistive Care
- Remote Diagnostic Devices
- Remote Monitoring Devices

Research Solutions
- Bioinformatics
- Drug Discovery
- Omics Related Research

Clinical Trials
- Decentralized Clinical Trials
- Clinical Trial Matching
- Data Collection Tools
- Clinical Trial Design

Telemedicine
- Teleconsultation
- Telepathology
- Teleradiology
- Telesurgery

Veterinarian
- Animal Health Forums
- Animal Imaging
- Animal Monitoring
- Omics Related Veterinary
- Televeterinary

Wellness
- Omics Related Applications
- Smart Equipment
- Wearables
- Wellness Apps
- Wellness Information Platform

Safety & Security
- Counterfeit Tracking
- Cybersecurity
- Pharmacovigilance

Healthcare Logistics
- Transportation Management
- On-demand Delivery

Others
- Contamination Management
- HCP Job Board
- Healthcare Marketing
- Social Enterprise
- Software Provider

Digital Health / HealthTech Cluster


Category

© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Overlapping Categories

Many ventures in the Clinical Trials cluster have developed solutions that span multiple categories within Galen Growth's Digital Health taxonomy. For instance, a venture specializing in Decentralised Clinical Trial tools may also offer a secure portal that integrates wearable device data and extracts the trial-relevant information, placing it in the Data Collection Tools category as well. As shown in the chart below, Data Collection Tools has the largest proportion of ventures focused solely on their primary solution, whereas ventures in Decentralised Clinical Trials tend to be the most diversified.




© 2024 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Venture Funding in Key Digital Health Clusters

Clinical Trial Design led the way in Digital Health funding from January to September 2025, securing $456 million across 11 deals. Taking the second spot, Clinical Trial Matching secured $294 million in capital. The significant funding directed toward these two categories highlig hts the accelerating momentum behind AI-powered platforms and tools that are transforming both healthcare delivery and biopharma development.

Top Funded Digital Health Clusters, H1 2025



	Digital Health Cluster	Total Funding Globally, YTD 2025	Rank in 2024	Largest Deal in YTD 2025
1	Clinical Trial Design	$456M	#4	Pathos $365M (Series D)
2	Clinical Trial Matching	$294M	#1	Autonomize AI $600M (Series A)
3	Decentralised Clinical Trials	$67M	#2	Lindus Health $55M (Series B)
4	Data Collection Tools	$47M	#3	Motivity $27M (Series B)

© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Alpha Forecaster™

Lindus Health is a clear choice

Lindus Health

Lindus Health

COUNTRY OF ORIGIN
United Kingdom

PRIMARY CATEGORY
Decentralised Clinical Trials

LATEST FUNDING
$55M (Series B)

THERAPEUTIC AREA
Disease Agnostic


INC. DATE
03 / 2021

MATURITY SCORE
73.3

DESCRIPTION

Lindus Health's mission is to help innovative companies make an impact, accelerate the pace of research and to make research more patient-centric. Lindus Health develops an end-to-end platform supporting decentralised, hybrid, or site-based clinical trials.

Venture Scores and Analysis




	Venture	Peer Group Average
Alpha Score	**73**	55
Momentum Index	**52**	46
Market Index	**62**	47
Money Index	**69**	40
Innovation Index	**76**	53
Team Signal	**71**	53
Partnership Signal	**89**	61

Full Profile in HealthTech Alpha

HEALTHTECH ALPHA

Access all the data behind this report and conduct your own analysis with *Alpha Edge*

Get started



Clinical Trials


Therapeutic Focus

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

2025 YTD Venture Funding in Key Therapeutic Areas

As of 2025 YTD, ventures offering disease-agnostic solutions for clinical trials have raised $175 million in funding. Oncology captured the top therapeutic spot with $569 million of venture capital deployed, while Mental Health jumped from eighth place into second place with $46 million.

Top Funded Therapeutic Areas, YTD 2025




Therapeutic Areas	Total Funding Globally, YTD 2025	Rank in 2024	Largest Deal in 2025
1 Oncology	$569M	#1	Transcarent $481M (Private Equity)
2 Mental Health	$46M	#8	Motivity $27M (Series B)
3 Rare Disease	$29M	#12	Citizen Health $30M (Series A)
4 Women's Health	$23M	#18	SeqOne Genomics $23M (Series B)
5 Neurology	$16M	#3	Science Corporation $104M (Strategic)

© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Oncology Tops the Funding Charts

Across the top five funded therapeutic areas in 2025 YTD, Oncology captured the highest number of deals and took the top spot for venture funding value. While there is a significantly higher number of disease-agnostic ventures than those that are disease-specific, these were not as successful at raising funding.



© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Alpha Forecaster™

Trialbee clearly places above its peers

trialbee

[Trialbee]

COUNTRY OF ORIGIN
Sweden

PRIMARY CATEGORY
Clinical Trial Matching

LATEST FUNDING
$13M (Series B)

THERAPEUTIC AREA
Disease Agnostic


INC. DATE
01 / 2011

MATURITY SCORE
65.8

DESCRIPTION

Trialbee is the leading global data and technology platform focused on patient matching and enrollment in clinical trials. Their flagship solution, Trialbee Hive™, leverages real-world data (RWD) and data science to match patients worldwide. Additionally, their Candidate Manager platform streamlines the process for matched patients to qualify and participate in clinical research. Trialbee collaborates with sponsors, CROs, virtual/decentralized sites, and software providers to meet patient enrollment goals and enhance clinical trial outcomes

Venture Scores and Analysis



	Venture	Peer Group Average
Alpha Score	66	49
Momentum Index	50	48
Market Index	46	36
Money Index	55	29
Innovation Index	76	44
Team Signal	65	55
Partnership Signal	63	58

Full Profile in HealthTech Alpha


Introducing HealthTech Alpha's CoPilot

Unparalleled Insights with GenAI-Powered Precision

Revolutionise Digital Health Research

Accelerated Decision-Making with Intelligent Data

Ensure a competitive edge with insights that no other platform can provide. Alpha CoPilot empowers users to make smarter, faster, and more informed decisions by seamlessly integrating GenAI search with HealthTech Alpha's comprehensive database.



Digital Innovation in Clinical Trials

Regional Snapshots

North America

Europe

Asia Pacific

Snapshot

United States

Unlocking Faster Clinical Trials in the U.S.

The Bottleneck in Drug Development

In the U.S., clinical trials remain the largest bottleneck in drug development — accounting for over half of total R&D costs and often lasting several years.

While breakthroughs in TechBio and AI have accelerated early-stage discovery, the greatest time and cost pressures now lie in the trial phase. Delays in patient recruitment, increasing protocol complexity, and high dropout rates continue to slow progress. Trials are becoming not only more expensive — with some exceeding $100 million per phase — but also more demanding, with stricter eligibility criteria, larger endpoints, and heavier data requirements.

Digital Acceleration and Emerging Solutions

The pandemic accelerated digital adoption, setting the stage for a new wave of innovation in clinical trials. AI-driven trial design, digital recruitment and matching, decentralised platforms, and advanced data collection tools are now proven to streamline operations, expand inclusivity, and improve regulatory outcomes.

The Need for Strategic Investment and Partnerships


Despite this progress, funding for clinical trial ventures in the U.S. has fallen by 46% over the past five years, while partnerships have dropped by more than half year-on-year — limiting the scale of these solutions.

With regulators offering clearer guidance and health systems investing in public trial data infrastructure, the moment is ripe for strategic investment and bold partnerships to transform U.S. clinical trials into faster, more efficient engines of medical progress.

Funding for U.S. Ventures in Clinical Trials



2021: $3.09 billion




2024: $1.17 billion

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


U.S. Dominates in Clinical Trial Innovation

The U.S. holds a leading position in digital clinical trial solutions, since it is home to 45% of ventures in this cluster. These ventures span a range of focuses, with the largest category (36%) dedicated to digital solutions for Clinical Trial Matching. Over the past five years, the sector has experienced a steady stream of exits, with mergers and acquisitions becoming the predominant exit route.

Share of Clinical Trials Ventures Founded in the USA, with Distribution by Category



Volume of Investor Exits (IPO, M&A, SPAC)




© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

United States H1 2025 Venture Funding

The U.S. and other major Digital Health hubs in N. America, by Funding Value

Country	Total Funding
United States	$628M
Canada	<$1M
Mexico	<$1M




© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


2025 Funding Flows to Late-Stage Ventures

2025 Digital Health funding mirrors global geopolitical unrest, as the broader venture capital market continues to face liquidity pressures and persistent uncertainty. With $533 million deployed, 85% of the funding so far in 2025 has gone to last-stage funding rounds. Despite capturing the smallest share of ventures (8%), ventures in the Clinical Trial Design category captured 58% of the funding deployed.

US Venture Funding Distribution, by Funding Stage



YTD 2025 Funding Distribution for US Ventures by Digital Health Cluster




© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


U.S. Ventures Partner to Expand the Ecosystem

Like the global ecosystem, the widespread adoption and impact of digital solutions for clinical trials in the U.S. relies on the collaboration of key healthcare stakeholders. Like other sectors, venture-to-venture partnerships (32%) help eliminate fragmented point solutions, enhancing convenience for consumers. By working closely with healthcare providers and pharmaceutical companies, ventures in this sector can develop solutions that are better integrated into their customers' workflows and facilitate a smoother transition from legacy systems.

Distribution of Partnerships, by Partner Industry Vertical (2021 – 2025)



Growth of Partnerships in the U.S. by Quarter and Share of Global Partnerships



© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Now is the Moment to Invest in U.S. Clinical Trial Ventures

Momentum Is Returning



- **Funding is rising:** Clinical trial venture funding up **1.8x YoY from H1 2024 to H1 2025**.
- **Strong exit performance:** Exit ratios remain solid, signaling **healthy investor returns**.
- **Validated use cases:** AI-driven design, recruitment, and data tools are **proving real-world impact**.

Market Gap = Opportunity



- Persistent inefficiencies in **trial design, recruitment, and data integration**.
- Only **8% of U.S. clinical trial ventures focus on Trial Design**, yet these ventures have captured **56% share of funding** in 2025 YTD.
- Room for innovators to **own the AI infrastructure layer** of clinical trials.

Partnering Potential



- **Partnership activity dipped** in late 2024–2025, but **biopharma interest remains strong**.
- Strategic collaborations can **unlock scale and validation** for emerging ventures.
- Now is the time to **re-engage industry players** ready to co-develop next-gen trial models.

© 2025 by Galen Growth - All rights reserved.

Snapshot


Europe

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Europe Has the Second-Largest Clinical Trials Ecosystem

Europe, the world's second-largest region for ventures focused on clinical trials, accounts for 34% of the global ecosystem and is actively engaging in mergers and acquisitions (M&A) to strengthen its regional landscape. Ventures span all categories within the Clinical Trials cluster, with Clinical Trial Matching being the most represented segment.

Share of Clinical Trial Ventures Founded in Europe, with Distribution by Category



Volume of Investor Exits (IPO, M&A, SPAC)




© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Europe YTD 2025 Venture Funding

Top 10 Countries in Europe by Funding Value

Country	Total Funding
United Kingdom	$55.0M
France	$51.8M
Poland	$10.2M
Belgium	$6.2M
Germany	$6.1M
Spain	$5.9M




© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Early Stage and Growth Stage Venture Funding in Europe Surges

European ventures experienced strong funding momentum in the second half of 2024 and the first half of 2025, in contrast to a more subdued investment climate in the U.S. A total of $135 million was deployed across 15 deals in Europe, underscoring the growing investor appetite for scaling late-stage companies across the region. 39% share of the investors' funds was deployed to ventures with solutions for managing Decentralised Clinical Trials.

European Venture Funding Distribution, by Funding Stage



Funding Distribution for European Ventures by Digital Health Cluster




© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


European Ventures Pushing for More Partnerships

Ventures in Europe rely on partnerships to confirm product/market fit and to get products into the competitive clinical trials market. Venture-to-venture partnerships, along with partnerships with biopharma companies, take the top 2 spots for partnerships. While partnerships surged in Europe in Q1 2025, Q2 and Q3 have been notably quieter.

Distribution of Partnerships, by Partner Industry Vertical (2021 – 2025)



Growth of Partnerships in Europe by Quarter and Share of Global Partnerships



© 2025 by Galen Growth - All rights reserved.

Snapshot


Asia Pacific

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Asia-Pacific Focuses on Decentralised Trial Management

The Asia-Pacific region is home to 15% of ventures focused on clinical trials. M&A activity is slow compared to other major global regions, with only three acquisitions and three IPOs in the past five years. Ventures span all categories within the Clinical Trials cluster, with Decentralised Clinical Trials standing out as the most represented segment.

Share of Clinical Trial Ventures Founded in APAC, with Distribution by Category



Volume of Investor Exits (IPO, M&A, SPAC)




© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Asia Pacific YTD 2025 Venture Funding

Funding activity for clinical trials ventures in the Asia Pacific has been nearly absent over the past year, with the sole notable round being a Seed raise of undisclosed value by South Korea's Urban Data Lab, a venture focused on data collection tools, in June 2025.




© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


APAC Focuses on Data-Collection Tools

In previous years, support for late-stage ventures was robust, with significant capital flowing into scaling operations and market expansion. Recent funding trends have shifted toward developing data collection tools that enable the digital transformation of clinical trials. Since there were no recorded funding values in 2025, the distribution by category is shown for 2024 – YTD 2025.

APAC Venture Funding Distribution, by Funding Stage



Funding Distribution for APAC Ventures by Digital Health Category (2024 – YTD 2025)




© 2025 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


2025 Partnership Activity Low in Asia Pacific

Partnership activity was strong in Asia Pacific across 2024, but ventures have struggle in the first 2 quarters of 2025 to connect to the ecosystem. Corporate collaborations spanned a wide range of industry verticals, with Academia and Pharmaceutical partnerships reaching 14% share each, and partnerships with Clinical Research Organisations (CROs) capturing 13% share of all regional partnerships over the past 5 years.

Share of Partnerships by Industry Vertical (2020 – YTD 2025)



Growth of Partnerships in Asia Pacific by Quarter and Share of Corporate Partnerships




© 2025 by Galen Growth - All rights reserved.

Industry’s Go-to-Reference Digital Health Research

We leverage our unmatched data and analyst team to research and publish unique go-to reference thematic reports on the Digital Health ecosystem.

- **Q2 2025 Digital Health Funding: From Hype to Health Impact**
- **Femtech’s Challenge: Growth, Gaps, and the Health Equity Imperative**
- **Consumer HealthTech: A Paradigm Shift in Healthcare**
- **Clinical Strength in Digital Health Innovation**
- **Pharmaceutical Digital Health Innovation Index**



Key Information

Key Information

Scope of Report

This report covers Digital Health ventures with incorporation date after 2002. The data is valid as of 11 Sept 2025.

Digital Health is defined as the intersection between healthcare and technology, and is also referred to as HealthTech. Digital Health does not include Biotech (protein research or pharmaceuticals), MedDev (devices that are mechanical and electronic in nature), neuro-stimulates, opioids and minimal-invasive instruments.
We recommend reviewing our taxonomy on the next page for further details.

Data Sourcing and Tracking

Galen Growth tracks a comprehensive inventory of key data points ranging from company demographics, funding and valuation to in-market capabilities on a continuously growing and curated list of HealthTech ventures drawn from global markets. Data is collated from primary research, public domain sources (press releases, news, public fillings), proprietary analytics and from its unique network.

The information is:

- Disclosed and undisclosed by nature
- Continuously updated with the latest data
- Curated from both direct and indirect verified sources
- Augmented with our proprietary algorithms

Each HealthTech Alpha Index and Score is calculated using proprietary algorithms and data points drawn from our carefully curated HealthTech Alpha database. We recommend reviewing the Digital Health Analytics section for further insights.

Key Terms and Definitions

BASE CURRENCY	USD
EARLY STAGE	All deals up to Series A stage
GROWTH STAGE	All deals at Series B & C stage
LATE STAGE	All deals at Series D & Beyond stage
EXIT	IPO, SPAC and M&A deals
HTA	HealthTech Alpha

Important Information

This report is provided solely for informational purposes and was prepared in good faith on the basis of public information available at the time of publication without independent verification. Numbers will be updated from to time to reflect information identified after the event.

Galen Growth does not guarantee or warrant the reliability or completeness of the data nor its usefulness in achieving any particular purposes.


Galen Growth shall not be liable for any loss, damage, cost or expense incurred by any reason because of any person's use or reliance on this report.

This report is a proprietary aggregation of publicly available and undisclosed data and shall not be forwarded or reproduced without the prior written consent of Galen Growth.

Research Inquiries

For more information about data, research and Galen Growth's proprietary algorithm contact: research@galengrowth.com for more information.

© 2025 by Galen Growth - All rights reserved.



GALEN GROWTH


Digital Health Clusters and Categories

With 66 Digital Health categories across 18 clusters, Galen Growth's comprehensive taxonomy streamlines venture discovery and analysis.

Health Management Solutions	Health Services Search	Health InsurTech
Medical Diagnostics	Medical Education	Online Health Communities
Online Marketplace	Patient Solutions	Population Health Management
Remote Devices	Research Solutions	Clinical Trials
Telemedicine	Veterinarian	Wellness
Safety & Security	Healthcare Logistics	Others

Mapping across the value chain

Further classification of target users and value propositions




© 2025 by Galen Growth - All rights reserved.

Alpha Forecaster™ Analytics

The Alpha Score is a 360° Venture Maturity assessment that aggregates four distinct and independent Alpha Indices

- Momentum index: evaluates the present performance and fitness of the venture relative to its ecosystem peers.
- Money index: quantifies the financial strength and wellbeing of the venture based on its financial history and investor quality.
- Market index: evaluates the health of the sector category and sub-category in which a startup competes
- Innovation index: evaluates the degree to which the venture is solving healthcare pain points



The Team Signal evaluates the strength of the venture's leadership team.

The Partnership Signal evaluates the strength of the venture's partnership network.

The Venture Similarity Score indicates the commonality of existing data points between startups within the HealthTech Alpha database.

The Venture Valuation estimates the current and next funding stage valuation of a venture based on mark-to-market calibration.


The Evidence Signal is an indicator of the amount of evidence that a venture has accumulated to confirm the benefit of its solution to the target customer.

© 2025 by Galen Growth - All rights reserved.

HEALTHTECH ALPHA

Explore the key themes driving the Digital Health ecosystem

- Research
- Telemedicine
- Oncology
- Neurology




HEALTHTECH ALPHA

Create your HealthTech Alpha account today

Better informed health innovation choices are just a click away with our best-in-class, private market data platform for Digital Health. Our comprehensive specialist data gives you all the information you need to make winning decisions.

Get started



Let’s Discuss How We Can Deliver Your Strategic Healthcare Goals

Galen Growth Inc
United States

Galen Growth Asia Pte Ltd
Singapore

Galen Growth GmbH
Switzerland

Contact Us

Galen Growth Asia
Singapore, Singapore
+65 8374 8584
dario.heymann@galengrowth.com

Galen Growth Europe
Basel, Switzerland
+41 79 610 1764
julien.desalaberry@galengrowth.com

Galen Growth USA
Boston, MA
+1 (617) 213 2983
julien.desalaberry@galengrowth.com